Merrimack Announces U.S. FDA Approval of ONIVYDE™ (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Trump says Canada's Bombardier must build jets in US or lose market access
- Qualcomm to issue warrant to Amazon for up to 25M shares
- Wall St slips as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Merrimack Pharmaceuticals (MACK) Weakness Creates Buying Opportunity, Mizuho Securities Says
October 23, 2015 6:51 AM EDTWeakness in Merrimack Pharmaceuticals (NASDAQ: MACK) following FDA approval of ONIVYDE presents a buying opportunity, according to Eric Criscuolo of Mizuho Securities. The firm reiterated an Outperform rating and price target of $16.
Criscuolo commented, "We think the 13% decline following news of ONIVYDE approval... More
Merrimack (MACK) Onivyde Labeling Appears as Expected, Says Mizuho Securities
October 22, 2015 2:14 PM EDTMizuho Securities maintained a Buy rating on Merrimack Pharmaceuticals (NASDAQ: MACK) with a price target of $16. Shares dropped 20% after Merrimack announced FDA approval for MM-398. In the view of analyst Eric Criscuolo, the label was as expected, despite the Black Box warning for diarrhea and... More
Merrimack Pharma (MACK) Drops Lower Following ONIVYDE Approval; Will Include 'Boxed Warning'
October 22, 2015 2:10 PM EDTMerrimack (Nasdaq: MACK) shares are down over 21 percent with heavy volume Thursday afternoon after the company... More
